Journal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 22, Issue 8, Pages E716-E729Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2022.03.013
Keywords
Lenalidomide multiple myeloma; Autologous stem cell transplant; Stem cell harvest; Apheresis multiple myeloma; Apheresis time multiple myeloma
Categories
Ask authors/readers for more resources
Prolonged lenalidomide treatment does not significantly affect stem cell collection in the context of modern mobilization regimens.
We investigated whether prolonged lenalidomide treatment impairs stem cell collection among patients with multiple myeloma mobilized with plerixafor or cyclophosphamide. There was no correlation between the duration of lenalidomide therapy and the number of stem cells collected, suggesting that prolonged treatment with lenalidomide is not a significant barrier to stem cell collection in the context of modern mobilization regimens. Introduction: Induction therapy for multiple myeloma is traditionally capped at 6 cycles of lenalidomide due to concerns that longer treatment compromises the ability to collect sufficient stem cells for autologous stem cell transplantation (ASCT). However, during the COVID-19 pandemic, many of our patients received prolonged lenalidomide induction due to concerns about proceeding to ASCT. We investigated whether prolonged induction with lenalidomide affects the efficacy of stem cell collection among patients mobilized with cyclophosphamide and/or plerixafor. Patients and methods: This single center, retrospective study included patients who were treated with lenalidomide induction regimens, received mobilization with cyclophosphamide or plerixafor, and underwent apheresis in preparation for ASCT. 94 patients were included, 40 of whom received prolonged induction with >6 cycles of lenalidomide containing regimen. Results: Patients who received prolonged induction were more likely to require >1 day of apheresis (38% vs. 15%; OR 3.45; P = .0154), and there was a significant correlation between the duration of lenalidomide treatment and the apheresis time required to collect sufficient cells for transplant (R-2 = 0.06423, P = .0148). However, there was no significant difference between patients who received prolonged induction and those who did not with respect to CD34(+) stem cell yields at completion of apheresis (9.99 vs. 10.46 cells/Kg, P = .5513) or on the first day of collection (8.29 vs. 9.59 cells/Kg, P = .1788). Conclusion: Among patients treated with >6 cycles of lenalidomide, mobilization augmented with cyclophosphamide and/or plerixafor will likely facilitate sufficient stem cell harvest to permit ASCT. (C) 2022 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available